Lupus patients may get new hope from engineered immune cells

NCT ID NCT06189157

Recruiting now Disease control Sponsor: Miltenyi Biomedicine GmbH Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 23 times

Summary

This study tests a new treatment called MB-CART19.1 for people with severe systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The trial has two phases: the first finds the safest dose, and the second checks if the treatment can put the disease into remission. About 29 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Otto-von-Guericke-Universität Magdeburg
RECRUITING

Magdeburg, Germany

Contact

Contact
Universitatsklinikum Tubingen - Medizinische Universitätsklinik Abt. II
RECRUITING

Tübingen, Germany

Contact

Contact
Universitätsklinikum Erlangen, Medizinische Klinik 3
NOT_YET_RECRUITING

Erlangen, Germany

Contact

Contact

Conditions

Explore the condition pages connected to this study.

SLE - SYSTEMIC LUPUS ERYTHEMATOSUS SLE - SYSTEMIC LUPUS ERYTHEMATOSUS